Pairing eloralintide with tirzepatide beat tirzepatide alone at 48 weeks, at 23.3% versus 14.8% weight loss. Up to about a quarter of people on the combo quit because of side effects.
Recap by typeshit. Full story at New Atlas.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A post hoc MRI look at 55 people, shown at EASD 2026, found average liver fat dropped from 8.8% to 3.1% by week 72. No placebo comparison was reported.
The appeal board went against its preliminary opinion. JUVE Patent says generic semaglutide could reach Europe as early as 2031 instead of 2037.
Loading…